Cure My Disease

Don't miss your cure!

 Log in / Sign up

First human study of VV261: a new pill under the microscope

NCT ID NCT07710326

Not yet recruiting Knowledge-focused Sponsor: Vigonvita Life Sciences Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This early-stage trial tests the safety and how the body handles VV261 tablets in healthy Chinese adults aged 18 to 45. Participants receive either VV261 or a placebo multiple times daily. Researchers measure drug levels in the blood and monitor for any side effects. The goal is to gather initial safety data before moving to larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
VV261 tablets
What this could lead to
If successful, this study could support further development of VV261 for potential future uses.
What could go wrong
This is an early-phase trial with only 16 healthy participants, so results may not predict effects in larger or patient populations. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, 230031, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.